E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Women with low reproductive capacity |
donne con insufficiente capacità riproduttiva |
|
E.1.1.1 | Medical condition in easily understood language |
Women with low reproductive capacity |
donne con insufficiente capacità riproduttiva |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002658 |
E.1.2 | Term | Anovulation |
E.1.2 | System Organ Class | 100000004860 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10016398 |
E.1.2 | Term | Female infertility |
E.1.2 | System Organ Class | 100000004872 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071102 |
E.1.2 | Term | Controlled ovarian hyperstimulation |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
compare the number of retrieved oocytes in the late start CF-alfa vs. early start CF-alfa in patients undergoing IVF |
confrontare il numero di ovociti ottenuti con il protocollo di somministrazione "early start" vs. il protocollo "late start" con Corifollitropina-alfa (CF-alfa) in pazienti sottoposte a Fecondazione in vitro |
|
E.2.2 | Secondary objectives of the trial |
Compare the two protocols with regard to the oocyte morphology (assessed by polarized light microscopy) the rate of clinical pregnancy to six weeks, the incidence of side effects and the degree of satisfaction of the patient |
Confrontare i due protocolli per quanto riguarda la morfologia ovocitaria (valutata mediante microscopia a luce polarizzata) il tasso di gravidanza clinica a sei settimane, l'incidenza di effetti indesiderati e il grado di soddisfazione della paziente |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age 18-43 years Tubal infertility or male infertility referred for IVF Willingness to undergo randomization |
Età 18-43 anni Infertilità tubarica o maschile con indicazione alla FIV Volontà di sottoporsi alla randomizzazione |
|
E.4 | Principal exclusion criteria |
absence of Polycystic ovaric syndrome hormonal therapy in the two months preceeding IVF Previous ovarian hyperstimulation syndrome Previous superovulation controlled with excessive response a basalantral follicle count >20 even benign tumors of the ovary, breast, uterus, pituitary gland or hypothalamus |
Ovaio policistico Terapia ormonale nei due mesi precedenti la FIV Pregressa sindrome da iperstimolazione ovarica Pregressa superovulazione controllata con risposta eccessiva Conta follicolare basale maggiore di 20 Tumori anche benigni di ovaio, mammella, utero, ipofisi o ipotalamo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of retrieved oocytes at US guided puncture |
Numero di ovociti recuperati al prelievo ecoguidato |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Pregnancy rate with either applied protocol; Safety and undesired effects of applied protocols |
Percentuale di gravidanza ottenuta con ogni tipo di protocollo appicato; Sicurezza ed effetti collaterali dei protocolli studiati |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12 months; 12 months |
12 mesi; 12 mesi |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Modalità di somministrazione |
Administration time |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Pregnancy test of the last enrolled patient |
Test di gravidanza dell'ultima paziente inclusa |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |